Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis by Weiming Liang, Weiming Liang, Zhijing Wang, Zhilong Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Duo Zhang, Chenchen Li

“…ObjectiveTo evaluate the efficacy and safety of programmed cell death protein 1 or its ligand (PD-1/L1) inhibitors as first-line therapy in advanced or metastatic urothelial carcinoma (mUC) who are ineligible for platinum-based chemotherapy.MethodA systematic search was conducted in four databases (Pubmed, Embase, Web of Science, and the Cochrane Library) to find articles that evaluate the effectiveness of first-line PD-1/L1 inhibitors for mUC, from the establishment of the databases to 22 November 2023. …”
Get full text

Studies of the Selective Removal of Micro-Quantities of Platinum(IV) Ions from Macro-Quantities of Model Solutions of Aluminium, Copper, Iron, Nickel and Zinc Chloride on Anion-Exchangers of Various Types by Z. Hubicki, G. Wójcik

“…Platinum has been widely applied as an industrial catalyst and consequently the recovery of noble metals from industrial wastes has become an economic issue. …”
Get full text

Low tumour interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.... by Seyer Safi, Axel Benner, Philipp Beckhove, Thomas Muley

Get full text

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm by Scott Goulden, Qin Shen, Robert L. Coleman, Cara Mathews, Matthias Hunger, Ankit Pahwa, Rene Schade

“…**Background:** Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite instability–high advanced or recurrent EC. …”
Get full text

Enhanced hydrogen evolution via nano-patterned Pt-based metallic glass and dynamic copper oxide foam formation by Fei-Fan Cai, Baran Sarac, Adnan Akman, Juan J. Londoño, Selin Gümrükcü, Lukas Schweiger, Martin Hantusch, Jan Schroers, Andreas Blatter, Annett Gebert, Florian Spieckermann, Jürgen Eckert

Subjects: Get full text

GARNET MINERALIZATION ASSOCIATED WITH LATE MAGMATIC AND HYDROTHERMAL-METASOMATIC PROCESSES IN DUNITES OF THE NIZHNY TAGIL CLINOPYROXENITE-DUNITE MASSIF, CENTRAL URALS by S.Yu. Stepanov, R.S. Palamarchuk, V.V. Shilovskikh, D.A. Artemiev, A.V. Korneev, A.K. Kozin

Subjects: Get full text

An optimized eDNA protocol for fish tracking in estuarine environments by Fouad El Baidouri, Alison W. Watts, Jeffrey T. Miller, Muriel Kelly, Joseph L. Sevigny, Heather Gilbert, W. Kelley Thomas

Subjects: Get full text

Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer by Sangsang Tang, Yangyang Li, Yifeng Fang, Mengyan Tu, Shenglong Wu, Yixuan Cen, Junfen Xu

Subjects: “…Platinum-resistant ovarian cancer…”
Get full text

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis by Xiaolian Peng, Jie Liu

“…IntroductionClinical trials have shown that PARP inhibitors are effective in treating patients with platinum-sensitive ovarian cancer. They have been indicated to improve progression-free survival or overall survival in patients with patients with platinum-sensitive ovarian cancer. …”
Get full text

Correction: Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study by Airi Fujimoto, Yoshimichi Koutake, Daisuke Hisamatsu, Noriko Ookubo, Yurika Yabuuchi, Go Kamimura, Tatsuo Kai, Aki Kozono, Takahiro Ootsu, Hiroto Suzuki, Keisuke Matsuo, Kimiko Kuwahara, Yoshita Oiwane, Yuko Nagata, Kenya Tanimoto, Eri Sato, Mei Suenaga, Tomohiro Uehara, Akira Ikari, Satoshi Endo, Yoichi Hiraki, Yosei Kawamata

Get full text

Evaluation of the Antitumor Effects of Platinum-Based [Pt(η1-C2H4-OR)(DMSO)(phen)]+ (R = Me, Et) Cationic Organometallic Complexes on Chemoresistant Pancreatic Cancer Cell Lines by Erika Stefàno, Luca Giulio Cossa, Federica De Castro, Erik De Luca, Viviana Vergaro, Giulia My, Gianluca Rovito, Danilo Migoni, Antonella Muscella, Santo Marsigliante, Michele Benedetti, Francesco Paolo Fanizzi

“…For the interesting cytotoxic activity observed on YAPC, further biological assays were performed, on this cancer cell line, to evaluate the apoptotic and antimetastatic properties of the considered platinum compounds (1 and 2). The cytotoxicity of 1 and 2 compounds appeared to be related to their intracellular accumulation, which was much faster than that of cisplatin. …”
Get full text

Crystal structure of chlorido-(5-nitro-2-phenylpyridine-κ2N,C)-[(methylsulfinyl)methane-κ1S]platinum(II), C13H13ClN2O3PtS by Zou Hao, Tan Wei, Zhang Jian-Guo

Get full text

Communicating with diversities by Tanya le Roux, Annelie Naudé

Subjects: “…South African platinum-mining industry…”
Get full text

Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trialResearch in context by Xiangyang Yu, Chujian Huang, Longde Du, Chunguang Wang, Yikun Yang, Xin Yu, Shengcheng Lin, Chenglin Yang, Hongbo Zhao, Songhua Cai, Zhe Wang, Lixu Wang, Xiaotong Guo, Baihua Zhang, Zhentao Yu, Jie He, Kai Ma

“…We designed this trial to explore the efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB NSCLC to facilitate further optimization of this therapeutic strategy. …”
Get full text

High levels of soluble P-selectin, neutrophil extracellular traps, and myeloperoxidase as risk factor of deep vein thrombosis in malignancy patients receiving platinum-based chemotherapy [version 1; peer review: 2 approved, 1 approved with reservations] by Ketut Suega, I Made Bakta, Ni Made Renny Anggreni Rena

“…VTE events increase the mortality rate of patients with cancer receiving platinum-based chemotherapy. Soluble P-Selectin, Neutrophil Extracellular Traps (NET), and myeloperoxidase (MPO) are risk factors associated with DVT in malignancy patients receiving platinum-based chemotherapy. …”
Get full text

Synthesis, Characterization and Antitumor Activity of cis-bis(acylthioureato) platinum(II) Complexes, cis-[PtL2] [HL1=N,N-Diphenyl-N'-Benzoylthiourea or HL2=N,N-diphenyl-N'-(p-nitrobenzoyl)thiourea] by Wilfredo Hernández, Evgenia Spodine, Juan Carlos Muñoz, Lothar Beyer, Uwe Schröder, Jorge Ferreira, Mario Pavani

Get full text

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE) by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

“…Key eligibility criteria are as follows: (1) advanced gastric or esophagogastric junction cancer, (2) histologically confirmed diagnosis of adenocarcinoma, (3) refractory to first-line treatment including fluoropyrimidines, platinum, and an anti-PD-1/PD-L1 antibody, (4) performance status of 0–1, and (5) at least one measurable lesion. …”
Get full text

The overview of modern approaches in treatment of triple negative breast cancer by A. A. Kharitonova, I. A. Smirnova, M. V. Kiseleva

Subjects: Get full text

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer by Michelle Lockley, Kathy Robinson, Rowan Miller, Charlie Gourley, Nicholas Counsell, Iain Mcneish, Trevor Graham, Uma Anne Mukherjee, Helen Hockings, Apini Patel, Priya Narayanan, Katie Wilkinson, Harjot Dhanda, Alexander R A Anderson

“…Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian tube and peritoneum whose disease has progressed at least 6 months after day 1 of the last cycle of platinum-based chemotherapy. …”
Get full text

The crystal structure of catena-poly[diaqua-m2-dicyanido-κ2 C:N-dicyanido-κ1 C-bis(4-(pyridin-4-yl)benzaldehyde-κ1N)iron(II)-platinum(II), C28H22N6O4PtFe by Lu Jitao, Wu Xiaolin, Zhang Youwei, Xiao Yufang

Get full text